Literature DB >> 19844754

Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression.

Sven Pålhagen1, Hongshi Qi, Björn Mårtensson, Jan Wålinder, Ann-Kathrine Granérus, Per Svenningsson.   

Abstract

The biochemical basis of major depression (MD) in Parkinson's disease (PD) is largely unknown. To increase our understanding of MD in PD patients, the levels of monoamine metabolites (HVA, 5-HIAA and MHPG), BDNF, orexin-A, IL-6 and corticosterone were examined in cerebrospinal fluid. The analyses were performed in MD patients with (n = 11) and without (n = 12) PD at baseline and after 12 weeks' of treatment with the antidepressant citalopram, and in patients with solely PD (n = 14) at baseline and after 12 weeks. The major findings were that PD patients with MD had significantly lower baseline levels of MHPG, corticosterone and IL-6 when compared to patients with solely MD. In response to citalopram treatment, patients with solely MD exhibited an expected decrease in 5-HIAA and MHPG levels which was not found in PD patients with MD. Moreover, the levels of BDNF and IL-6 were lower in PD patients with MD compared with patients with solely MD after treatment with citalopram. Thus, the biochemical basis and the response to citalopram differ between PD patients with MD and patients with solely MD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19844754     DOI: 10.1007/s00415-009-5353-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

Review 1.  Autoregulation of serotonin neurons: role in antidepressant drug action.

Authors:  G Piñeyro; P Blier
Journal:  Pharmacol Rev       Date:  1999-09       Impact factor: 25.468

Review 2.  The mesolimbic dopamine reward circuit in depression.

Authors:  Eric J Nestler; William A Carlezon
Journal:  Biol Psychiatry       Date:  2006-03-29       Impact factor: 13.382

3.  Circulating levels of corticotrophin and cortisol after infusions of L-DOPA, dopamine and noradrenaline, in man.

Authors:  C S Wilcox; M J Aminoff; J G Millar; J Keenan; M Kremer
Journal:  Clin Endocrinol (Oxf)       Date:  1975-03       Impact factor: 3.478

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 5.  Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications.

Authors:  Robert M Post
Journal:  J Psychiatr Res       Date:  2007-01-18       Impact factor: 4.791

6.  Low levels of ventricular CSF orexin/hypocretin in advanced PD.

Authors:  X Drouot; S Moutereau; J P Nguyen; J P Lefaucheur; A Créange; P Remy; F Goldenberg; M P d'Ortho
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

7.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.

Authors:  Jing Zhang; Izabela Sokal; Elaine R Peskind; Joseph F Quinn; Joseph Jankovic; Christopher Kenney; Kathryn A Chung; Steven P Millard; John G Nutt; Thomas J Montine
Journal:  Am J Clin Pathol       Date:  2008-04       Impact factor: 2.493

8.  Suppressed neuroendocrine stress response in depressed women on job-stress-related long-term sick leave: a stable marker potentially suggestive of preexisting vulnerability.

Authors:  Kristina Wahlberg; Per Hamid Ghatan; Sieglinde Modell; Ake Nygren; Martin Ingvar; Marie Asberg; Markus Heilig
Journal:  Biol Psychiatry       Date:  2008-12-05       Impact factor: 13.382

9.  L-Dopa-induced release of cerebral monoamines.

Authors:  K Y Ng; T N Chase; R W Colburn; I J Kopin
Journal:  Science       Date:  1970-10-02       Impact factor: 47.728

10.  Diurnal variation of plasma corticosterone in depression.

Authors:  J R Seckl; J C Campbell; C R Edwards; J E Christie; L J Whalley; G M Goodwin; G Fink
Journal:  Psychoneuroendocrinology       Date:  1990       Impact factor: 4.905

View more
  25 in total

1.  Imipramine ameliorates pain-related negative emotion via induction of brain-derived neurotrophic factor.

Authors:  Seiko Yasuda; Mitsuhiro Yoshida; Hirotaka Yamagata; Yasutake Iwanaga; Hiromi Suenaga; Kozo Ishikawa; Masako Nakano; Satoshi Okuyama; Yoshiko Furukawa; Shoei Furukawa; Toshizo Ishikawa
Journal:  Cell Mol Neurobiol       Date:  2014-08-26       Impact factor: 5.046

Review 2.  Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.

Authors:  Mathieu Nollet; Samuel Leman
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

4.  Monoamines and cortisol as potential mediators of the relationship between exercise and depressive symptoms.

Authors:  Lara S F Carneiro; Maria Paula Mota; Maria Augusta Vieira-Coelho; Rita C Alves; António Manuel Fonseca; José Vasconcelos-Raposo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-08-02       Impact factor: 5.270

5.  Interleukin 6 and complement serum level study in Parkinson's disease.

Authors:  Branislav Veselý; Michal Dufek; Vojtech Thon; Miroslav Brozman; Silvia Királová; Tatiana Halászová; Eva Koriťáková; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2018-02-12       Impact factor: 3.575

6.  Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression.

Authors:  Alexandre K Wang; Brian J Miller
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

Review 7.  Depression in Parkinson disease--epidemiology, mechanisms and management.

Authors:  Dag Aarsland; Sven Påhlhagen; Clive G Ballard; Uwe Ehrt; Per Svenningsson
Journal:  Nat Rev Neurol       Date:  2011-12-26       Impact factor: 42.937

8.  Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression.

Authors:  Mathieu Nollet; Philippe Gaillard; Arnaud Tanti; Virginie Girault; Catherine Belzung; Samuel Leman
Journal:  Neuropsychopharmacology       Date:  2012-06-20       Impact factor: 7.853

Review 9.  Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?

Authors:  Christopher J Barnum; Malú G Tansey
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

10.  Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum.

Authors:  Daniel Lindqvist; Eli Kaufman; Lena Brundin; Sara Hall; Yulia Surova; Oskar Hansson
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.